And after last week's biotech drug price news, Holmes
reassured CNBC that "We are advocating that transparency on
pricing is essential, and one of the most exciting things about
what we've done is that physicians will look at our prices and
call up other labs and say 'if you don't match these prices we're
not sending you our patients.'"